BioSpace News Archive

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development

Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has entered into a license agreement with Morehouse School of Medicine for certain patents

Liquid Diagnostics announced today the development and successful CLIA validation of a home-collection assay for the quantitative testing of COVID-19 antibodies using saliva. It is now possible for individuals to monitor the level of their COVID-19 antibodies over time without leaving home. This test utilizes the proprietary

Wolters Kluwer, Health , a global provider of trusted clinical technology and evidence-based solutions, has announced the integration of DoseMeRx™ , a Tabula Rasa Healthcare precision dosing solution, with Sentri7’s Antimicrobial Stewardship (AMS) solution. With a single

AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced the Journal of Orthopaedic Surgery and Research published the company’s science

Rational Vaccines, a vaccine biotech firm based in Cambridge, Mass., points to the proven science of live-attenuated viruses in vaccine development as key to the company’s commitment to the development platform.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today responded to recent attacks by short sellers containing inaccurate and misleading information regarding scientific research published by Penumbra’s co-founder and Chief Innovator, Arani Bose , MD.

The importance of involving patients in the decision-making process for orthopaedic surgical procedures is the focus of a new review article published in the December issue of the Journal of the American Academy of Orthopaedic Surgeons®.

Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease, announced key updates on veverimer’s development program, regulatory status and patent protection.